Pharma Stocks Below 1000

The table below shows the Pharma Stocks Below 1000 based on the Highest Market Capitalization.

Content: 

• What are Pharma Stocks?
• Best Pharma Stocks In India Below 1000
• Top Pharma Stocks Below 1000
• List Of best Pharma Stocks In India Below 1000
• Top 10 Pharma Stocks in India Below 1000
• Who Should Invest In Pharma Stocks Below 1000?
• How To Invest In The Pharma Stocks Below 1000?
• Performance Metrics Of Pharma Stocks Below 1000
• Benefits Of Investing In Pharma Stocks Below 1000
• Challenges Of Investing In Pharma Stocks Below 1000
• Introduction to Pharma Stocks Below 1000
• Top Pharma Stocks below 1000 – FAQs

What are Pharma Stocks?

Pharma stocks refer to shares of companies operating in the pharmaceutical industry. These companies research, develop, manufacture, and distribute pharmaceutical products, including prescription drugs, over-the-counter medications, and biotechnology products. Pharma stocks may also encompass companies involved in medical research, clinical trials, and healthcare services. Examples include pharmaceutical giants, biotech firms, and companies specializing in generic drugs or specialty pharmaceuticals.

Best Pharma Stocks In India Below 1000

The table below shows the Best Pharma Stocks In India Below 1000 based on 1 Year Return. 

Top Pharma Stocks Below 1000

The table below shows Top Pharma Stocks Below 1000 based on the highest day Volume.

List Of best Pharma Stocks In India Below 1000

The table below shows List Of best Pharma Stocks In India Below 1000 based on the PE Ratio. 

Top 10 Pharma Stocks in India Below 1000

The table below shows Top 10 Pharma Stocks in India Below 1000 based on the 6 month return. 

Who Should Invest In Pharma Stocks Below 1000?

Investing in pharma stocks below 1000 can appeal to a wide range of investors. It may suit those seeking exposure to the healthcare sector with a moderate budget, including individuals interested in pharmaceutical innovations and medical advancements. Additionally, investors looking for defensive stocks with stable earnings and dividend yields, or those aiming to diversify their portfolios with healthcare investments may find pharma stocks below Rs.1000 attractive.

How To Invest In The Pharma Stocks Below 1000?

To invest in pharma stocks below Rs.1000, start by researching companies within the pharmaceutical sector. Identify leading pharmaceutical companies with stocks trading below Rs.1000 on the stock market. Open a brokerage account with a reputable platform, deposit funds, and place buy orders for the selected pharma stocks within your budget. Monitor your investments regularly and stay informed about industry developments and company performance.

Performance Metrics Of Pharma Stocks Below 1000

Performance metrics of Pharma Stocks Below 1000 Rs may include:

1. Revenue Growth: Reflects the rate at which the group’s companies increase their sales over time.

2. Earnings Per Share (EPS): Indicates the profitability of each share and the potential for dividend payouts.

3. Return on Equity (ROE): Measures how effectively the group’s companies are using shareholders’ equity to generate profits.

4. Price-to-Earnings (P/E) Ratio: Compares the current market price of the stock to its earnings per share, providing insight into its valuation.

5. Dividend Yield: Represents the percentage of dividends paid relative to the stock’s price, indicating the income generated for shareholders.

6. Debt-to-Equity Ratio: Measures the level of debt financing compared to equity financing, assessing the group’s financial leverage.

7. Total Shareholder Return (TSR): Reflects the total return generated for shareholders, including dividends and capital appreciation.

Benefits Of Investing In Pharma Stocks Below 1000

Advantages of investing in  Pharma Stocks Below Rs.1000 :

1. Growth Potential: Pharma stocks below Rs.1000 offer the potential for significant growth, especially if the companies have promising drug pipelines or are entering new markets.
2. Defensive Nature: The healthcare sector, including pharmaceuticals, tends to be defensive, as demand for healthcare products remains relatively stable even during economic downturns.
3. Dividend Income: Many pharmaceutical companies pay dividends, providing a source of income for investors.
4. Innovation Opportunities: Investing in pharma stocks below Rs.1000 allows investors to participate in the innovative developments and breakthroughs in the pharmaceutical industry.
5. Diversification: Adding pharma stocks to a portfolio below Rs.1000 can diversify risk and enhance overall portfolio performance, particularly if other sectors are underperforming.

Challenges Of Investing In Pharma Stocks Below 1000

Investing in Pharma Stocks Below 1000 Rs comes with certain challenges:

1. Regulatory Risks: Pharma stocks face regulatory challenges, such as drug approvals, pricing regulations, and patent expirations, which can impact company earnings and stock performance.
2. Clinical Trials: Investing in pharma stocks below Rs.1000 carries the risk of clinical trial failures, which can lead to setbacks in drug development and significant losses for investors.
3. Competition: The pharmaceutical industry is highly competitive, with companies vying for market share and facing competition from generics, biosimilars, and other innovative therapies.
4. Patent Expirations: Patent expirations on key drugs can result in revenue declines for pharmaceutical companies, leading to stock price volatility.
5. Litigation Risks: Pharma companies may face legal challenges related to patent infringement, product liability, or regulatory violations, which can result in financial penalties and reputational damage.

Introduction to Pharma Stocks Below 1000

Zydus Lifesciences Ltd

The Market Cap of Zydus Lifesciences Ltd is ₹88,865.55 crore. The stock’s 1-month return is -0.92%, while its 1-year return is -12.99%. It is currently 3.41% away from its 52-week high.

Zydus Lifesciences Ltd, formerly known as Cadila Healthcare, is a major Indian pharmaceutical company that develops and manufactures generic drugs, vaccines, biosimilars, and wellness products. It operates globally across regulated and semi-regulated markets with a strong focus on research and innovation. Zydus is well-recognized for its vertically integrated model, extensive R&D infrastructure, and an expanding portfolio of specialty and complex generics.

Despite a dip in its stock price over the past year, Zydus has retained a solid foundation within the pharmaceutical space. The minor gap from its 52-week high suggests relative market confidence. With continual regulatory approvals and product launches, Zydus is positioned to gain from the growing global demand for healthcare. Its strategic pipeline and consistent focus on affordability and access enhance its long-term growth potential.

Laurus Labs Ltd

The Market Cap of Laurus Labs Ltd is ₹33,711.37 crore. The stock’s 1-month return is 8.48%, while its 1-year return is 41.46%. It is currently 62.64% away from its 52-week high.

Laurus Labs Ltd is a leading pharmaceutical and biotechnology company specializing in active pharmaceutical ingredients (APIs), formulations, and synthesis. It serves customers across more than 50 countries and is known for its expertise in antiretroviral and oncology drugs. The company has strategically diversified into biotechnology, CDMO services, and APIs for chronic therapies, which has led to robust revenue streams.

The stock has delivered strong annual returns, reflecting its growth trajectory and business expansion. However, its significant distance from the 52-week high may indicate market volatility or profit booking after sharp rallies. With continued investment in manufacturing and innovation, Laurus is well-positioned to capitalize on both domestic and export opportunities, especially in the API and biosciences space.

Piramal Pharma Ltd

The Market Cap of Piramal Pharma Ltd is ₹29,382.02 crore. The stock’s 1-month return is 9.19%, while its 1-year return is 56.78%. It is currently 63.00% away from its 52-week high.

Piramal Pharma Ltd operates in contract development and manufacturing (CDMO), complex hospital generics, and consumer healthcare. It is a demerged entity from Piramal Enterprises and has built a strong global footprint with a diversified business model. Its CDMO segment serves leading global pharma companies, and the consumer healthcare line includes popular over-the-counter products.

The company has posted impressive returns over the year, suggesting strong investor sentiment and business performance. The substantial gap from its 52-week high, however, highlights either prior rallying or cautious correction. As the pharmaceutical CDMO market continues to grow, Piramal Pharma is likely to benefit from global outsourcing trends, especially due to its FDA-compliant facilities and technical capabilities.

Alembic Pharmaceuticals Ltd

The Market Cap of Alembic Pharmaceuticals Ltd is ₹16,638.09 crore. The stock’s 1-month return is 2.60%, while its 1-year return is -11.77%. It is currently 17.48% away from its 52-week high.

Alembic Pharmaceuticals Ltd is a legacy Indian pharmaceutical company with over a century of experience in producing branded and generic formulations. It has built a robust presence in the United States and emerging markets, with a strategic emphasis on regulated generics, active pharmaceutical ingredients, and specialty drugs. Alembic continues to invest heavily in R&D and manufacturing infrastructure.

While the stock has faced downward pressure over the past year, it has shown short-term recovery. The company’s focus on complex generics, ophthalmic solutions, and injectables may enhance growth in coming years. Alembic’s legacy and evolving pipeline continue to be its core strengths, offering potential for long-term investment stability.

Jubilant Pharmova Ltd

The Market Cap of Jubilant Pharmova Ltd is ₹14,570.92 crore. The stock’s 1-month return is 6.41%, while its 1-year return is 36.34%. It is currently 48.44% away from its 52-week high.

Jubilant Pharmova Ltd operates in the pharmaceutical, contract research, and drug discovery sectors. With operations in over 100 countries, the company has built a strong portfolio in specialty pharmaceuticals and proprietary research. Its manufacturing plants cater to regulated markets including the US, Canada, and Europe, supported by in-house research capabilities.

The stock has delivered strong returns in the last year, indicating strategic execution and rising investor confidence. However, the large distance from its 52-week high suggests room for further growth or prior volatility. Continued expansion in global markets, new launches, and strong compliance record may bolster long-term shareholder value.

Natco Pharma Ltd

The Market Cap of Natco Pharma Ltd is ₹14,399.54 crore. The stock’s 1-month return is 1.77%, while its 1-year return is -16.24%. It is currently 13.73% away from its 52-week high.

Natco Pharma Ltd is known for its focus on niche molecules, oncology, and specialty products. The company has carved a space in complex generics and backward-integrated manufacturing, particularly in the US market. Its product pipeline includes a mix of Paragraph IV filings, first-to-file opportunities, and high-value APIs.

Despite subdued annual performance, the minimal gap from the 52-week high shows improving sentiment. Natco’s innovation-driven approach and efforts to enter under-penetrated markets offer promising prospects. If regulatory approvals align with commercial rollouts, the stock has the potential to recover and perform well in the medium term.

Blue Jet Healthcare Ltd

The Market Cap of Blue Jet Healthcare Ltd is ₹12,774.86 crore. The stock’s 1-month return is -14.36%, while its 1-year return is 91.46%. It is currently 115.00% away from its 52-week high.

Blue Jet Healthcare Ltd focuses on specialty pharmaceuticals and contrast media APIs used in diagnostic imaging. The company supplies to regulated markets like the US, Europe, and Japan, and has strong relationships with multinational clients. It is known for its niche market presence and quality-focused manufacturing processes.

The impressive annual return reflects strong debut performance or market re-rating. However, the extreme distance from its 52-week high could suggest recent volatility or speculative highs. As the company stabilizes and scales operations further, continued innovation and contract wins could drive sustainable growth.

Granules India Ltd

The Market Cap of Granules India Ltd is ₹11,263.73 crore. The stock’s 1-month return is -1.63%, while its 1-year return is 11.38%. It is currently 18.93% away from its 52-week high.

Granules India Ltd is a vertically integrated pharmaceutical company known for producing finished dosages, APIs, and PFIs. Its product portfolio spans pain management, anti-infectives, and chronic therapies. With a strong presence in the US and Europe, Granules emphasizes cost-efficiency and high-volume manufacturing.

The stock has delivered modest gains over the year but remains competitively positioned. Its commitment to quality, regulatory compliance, and capacity expansion support steady growth. Strategic collaborations and margin improvement plans are expected to play key roles in driving future performance.

Marksans Pharma Ltd

The Market Cap of Marksans Pharma Ltd is ₹9,562.21 crore. The stock’s 1-month return is 7.55%, while its 1-year return is 20.84%. It is currently 64.25% away from its 52-week high.

Marksans Pharma Ltd is a growing pharmaceutical company focused on formulations for the US, UK, and Australian markets. The company specializes in oral solid dosages and has a broad portfolio of OTC and prescription products. It has steadily increased its presence in regulated markets through acquisitions and R&D.

Despite strong yearly returns, the large gap from the 52-week high hints at recent corrections or profit booking. The company’s consistent expansion, compliance record, and product pipeline provide optimism for long-term investors. Enhanced R&D investment and market diversification remain key growth drivers.

Akums Drugs and Pharmaceuticals Ltd

The Market Cap of Akums Drugs and Pharmaceuticals Ltd is ₹7,305.26 crore. The stock’s 1-month return is -7.23%, while its 1-year return is -37.31%. It is currently 23.25% away from its 52-week high.

Akums Drugs and Pharmaceuticals Ltd is one of India’s largest contract manufacturing pharmaceutical companies. It caters to a wide array of therapeutic segments and produces formulations for several leading domestic and multinational brands. Its diversified customer base and manufacturing scale give it a significant advantage in third-party manufacturing.

Despite a challenging year in the stock market, Akums holds potential due to its solid client base and production capabilities. A revival in demand and scaling of newer product lines could help reverse sentiment. Operational efficiencies and new client acquisitions may also uplift future performance.

Top Pharma Stocks below 1000 – FAQs

Here are some of the Best Stock Research Articles listed based on Top Sectors (Industries), Market Cap, and Fundamental Analysis Factors:

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.